Somewhere between the salmon-oil capsules at CVS and the "ask your doctor" fine print sits one of the most persistent health beliefs in America: that omega-3 fatty acids protect your heart. It's a claim built on genuinely promising early trials, decades of marketing momentum, and a supplement industry that has never met a hedge it liked. The actual evidence, when you look at what's been published recently, tells a narrower story than the capsule bottle implies.
What a New Trial Actually Found — and Who It's About
The most concrete recent data point is a randomized trial published in the New England Journal of Medicine testing daily omega-3 supplementation in patients on maintenance hemodialysis. The topline result: serious cardiovascular events occurred at a lower rate in the omega-3 group than in the placebo group. That's a real, positive finding — but it's worth sitting with exactly who was studied. Hemodialysis patients are a distinct, high-risk population with cardiovascular physiology that doesn't generalize cleanly to a healthy 45-year-old taking fish oil because a podcast recommended it. Without more detail available from that trial's public summary, I'd resist extrapolating its result outward. A benefit in dialysis patients is not the same claim as "omega-3 prevents heart attacks," and conflating the two is exactly the kind of move wellness marketing loves and evidence-based medicine should punish.
The Bigger Reviews Disagree With Each Other, Not Just With the Marketing
Zoom out to the general population, and the picture gets genuinely contested — not because researchers are sloppy, but because different reviews weight the same trial data differently. A 2020 Cochrane review, widely regarded as the strictest bar in evidence synthesis, pooled dozens of randomized trials covering well over a hundred thousand participants and found that long-chain omega-3 supplementation made little to no difference on all-cause mortality, overall cardiovascular events, or stroke, with those null results graded as high-certainty. It did find a small, low-certainty signal for reduced coronary heart disease events and CHD mortality specifically — the kind of modest, hedged finding that shouldn't be rounded up to "omega-3 protects your heart" or rounded down to "omega-3 does nothing" (as summarized by Proco).
A separate 2019 meta-analysis in the Journal of the American Heart Association, pooling a different slice of trials, reached a more favorable conclusion — but largely by excluding one specific, heavily litigated trial (REDUCE-IT) whose inclusion or exclusion swings the results meaningfully (as summarized by Proco). That's the tell for anyone evaluating this literature: when a meta-analysis's conclusion depends on whether you keep or drop one trial, you're not looking at a settled question. You're looking at a live methodological argument that happens to have two different answers depending on which side of the argument you land on.
A 2025 systematic review and meta-regression attempted to reconcile this exact tension across the broader omega-3 and cardiovascular literature, which tells you the field still considers the question open enough to warrant another full pass at the data (Mattumpuram et al.). That a fresh meta-regression was worth publishing in 2025 is itself evidence that nobody has closed this file.
What the Official Guidance Actually Says
For what it's worth, the NIH's own consumer-facing position is notably restrained. Its fact sheet on omega-3 fatty acids frames the evidence on cardiovascular health as an active area of research rather than a settled recommendation, and it distinguishes dietary omega-3 intake (fish, certain oils) from supplement-form EPA/DHA, which is a distinction the supplement aisle rarely bothers to make (NIH Office of Dietary Supplements).
The Honest Summary
If you're a healthy adult without kidney disease, the evidence for fish oil capsules meaningfully lowering your heart attack or stroke risk is thin and inconsistent — a small, low-certainty signal on coronary outcomes specifically, buried inside reviews that disagree with each other on methodology. If you're on dialysis, there's now a positive randomized trial worth discussing with your nephrologist. Those are two different conversations, and the marketing has spent twenty years pretending they're the same one. Watch for whether the 2025 meta-regression's full findings, once more broadly available, manage to settle the REDUCE-IT question one way or the other — that's the fight actually driving this debate, not the fish oil itself.